Analyzing the literature data available to us, we can conclude that for the first time we have made an experimental and simultaneous assessment of the expression levels of 11 genes from the caspase family (the CASP1, CASP2, CASP3, CASP4, CASP5, CASP6, CASP7, CASP8, CASP9, CASP10, and CASP14 genes) in patients diagnosed with triple-negative breast cancer. This evidence concerns the gene CASP3 and triple-negative breast carcinoma.